<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397019</url>
  </required_header>
  <id_info>
    <org_study_id>DPSG 2010-01</org_study_id>
    <nct_id>NCT01397019</nct_id>
  </id_info>
  <brief_title>Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours</brief_title>
  <official_title>Chemotherapy for Patients With Locally Advanced Pancreatic Cancer With Additional Chemo-radiotherapy for Patients With Borderline Resectable Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treating patients with initial local non-resectable pancreatic cancer with a combination of
      oxaliplatin, irinotecan &amp; 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in
      potentially resectable patients, will result in a high rate of tumor shrinkage allowing
      subsequent resection in patients with initial borderline resectable tumors and improved
      overall survival for all patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer (PC) is the third most common gastrointestinal malignancy and one of the
      top ten leading causes of cancer deaths in the Western world. Patients with PC can be divided
      into three subgroups; resectable (rPC), locally advanced (LAPC) and metastatic (mPC). For
      patients with rPC surgery offers the best chance for long term survival. However it is
      estimated that only 20% of patients have rPC at the time of diagnosis. For patients with
      LACP, invasion of local large vessels is most often the cause for non-resectability. The
      median survival of these patients is between 6 to 12 months and long term survival in is
      extremely rare. The optimal treatment of LAPC is controversial. Treatment strategies vary
      between attempts to &quot;downstage&quot; the tumour to rPC, or treat the patients in a palliative
      setting only. Phase II studies and retrospective series have evaluated various treatments
      regimens and strategies including chemotherapy and radiotherapy (RT) alone or in combination
      - chemoradiotherapy (CRT). Results from these trials give no clear answer regarding the best
      treatment strategy. However, data from several studies shows that treatment of LAPC may
      result in shrinkage of the tumour, and thus potentially lead to a resection; also data
      suggests that CRT after chemotherapy improves treatment efficacy. Recent data from patients
      with mPC has show a combination of oxaliplatin, irinotecan and 5-FU (FOLFIRINOX) increases
      response rates from 10% to 30% and median survival to 11.1 months. The promising efficacy
      makes it natural to attempt this treatment in patients with LAPC.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year survival rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, irinotecan, 5-FU &amp; leucovorin</intervention_name>
    <description>FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors</description>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (major)

          -  non-metastatic pancreatic cancer

          -  Performance status 0-1

          -  Bilirubin &lt; 1.5 UNL

          -  Written informed consent

        Exclusion Criteria: (major)

          -  no prior abdominal radiotherapy

          -  no prior chemotherapy for pancratic cancer

          -  no severe comorbidity

          -  patients must be able to undergo potential abdominal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jon K Bjerregaard, MD</last_name>
    <phone>+45 65413834</phone>
    <email>jon.bjerregaard@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Pfeiffer, Professor</last_name>
    <phone>+45 6541 2921</phone>
    <email>per.pfeiffer@ouh.regionsyddanmark.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Ladekarl, MD</last_name>
      <phone>+45 8949 2565</phone>
    </contact>
    <investigator>
      <last_name>Morten Ladekarl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benny V Jensen, MD</last_name>
      <phone>+45 3868 3868</phone>
      <email>bevi@heh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Benny V Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon K Bjerregaard, MD</last_name>
      <phone>+45 6541 3834</phone>
      <email>jon.bjerregaard@ouh.regionsyddanmark.dk</email>
    </contact>
    <contact_backup>
      <last_name>Per Pfeiffer, Professor</last_name>
      <phone>+45 6541 2921</phone>
      <email>per.pfeiffer@ouh.regionsyddanmark.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Per Pfeiffer, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon K Bjerregaard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael B Mortensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

